Press Release Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Aug 12
Press Release INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Bloom Energy Corporation (NYSE: BE) Investors with Substantial Losses Have Opportunity to Lead the Bloom Energy Class Action Lawsuit Aug 12